Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Moderate Buy" from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $35.70.

VRDN has been the topic of a number of research reports. Wells Fargo & Company restated an "equal weight" rating and issued a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Needham & Company LLC reissued a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Royal Bank of Canada upped their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Tuesday, December 17th. HC Wainwright reissued a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Finally, TD Cowen started coverage on Viridian Therapeutics in a report on Monday, November 25th. They set a "buy" rating on the stock.

Viridian Therapeutics Price Performance

Shares of VRDN traded down $0.06 during mid-day trading on Thursday, hitting $15.26. 1,790,382 shares of the company were exchanged, compared to its average volume of 1,157,942. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a 1-year low of $11.40 and a 1-year high of $27.20. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -3.54 and a beta of 1.05. The company has a 50 day moving average of $17.02 and a 200-day moving average of $19.72.

Remove Ads

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Analysts expect that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRDN. California State Teachers Retirement System grew its holdings in shares of Viridian Therapeutics by 18.0% during the 4th quarter. California State Teachers Retirement System now owns 54,710 shares of the company's stock worth $1,049,000 after purchasing an additional 8,344 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Viridian Therapeutics by 29.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,782 shares of the company's stock valued at $2,220,000 after buying an additional 26,286 shares during the last quarter. Tang Capital Management LLC boosted its stake in Viridian Therapeutics by 11.1% during the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock worth $47,789,000 after buying an additional 250,000 shares during the period. Rafferty Asset Management LLC boosted its stake in Viridian Therapeutics by 90.8% during the fourth quarter. Rafferty Asset Management LLC now owns 172,960 shares of the company's stock worth $3,316,000 after buying an additional 82,309 shares during the period. Finally, ProShare Advisors LLC increased its position in shares of Viridian Therapeutics by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 20,584 shares of the company's stock valued at $395,000 after acquiring an additional 8,761 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.